Samuel Denmeade, MD
Evaluation of Bindarit, a Novel Inhibitor of the CCL2 Chemokine Axis, as Therapy for Metastatic Prostate Cancer Dr. Denmeade is testing a medication called Bindarit – an orally active compound...Read More
William L. Redmond
Dr. Redmond earned a BS in Biology from the University of California – Davis and a PhD in immunology from the Scripps Research Institute. He is currently a Postdoctoral Fellow...Read More
Karen Sfanos
Determining the link between dietary carcinogens, pathogenic bacteria and IL-6 levels in prostate cancer initiation and progression As our understanding of the complexities of human cancer deepens, it is increasingly...Read More
Martin Lukas Sos
Targeting MYC-dependent metabolism in prostate cancer The gene MYC regulates normal cellular metabolism. Mutations in MYC result in the unregulated expression of several genes involved in cell proliferation, resulting in...Read More
Luke Selth
Androgen receptor splice variants: novel drivers of castration-resistant prostate cancer The androgen receptor (AR), which mediates the action of male sex hormones, androgens, fuels prostate cancer. Therefore, the primary treatment...Read More
Ganesh Raj, MD, PhD
Dr. Ganesh Raj is a surgeon-scientist with both an active clinical practice and devoted research laboratory who specializes in all aspects of urologic oncology, including the treatment of prostate, bladder,...Read More
Shancheng Ren
The role of recurrent gene fusion SDK1-AMACR in prostate cancer Gene fusions are the erroneous juxtaposition of two genes that do not normally lie next to each other on the...Read More
Paul Nguyen
Identification and integration of clinical features, genetic factors, and biomarkers to optimize prostate cancer risk stratification and treatment selection One of the most pressing dilemmas in the care of patients...Read More
David Mulholland
Evaluating the contribution of AR deficient stem/progenitor cells in Castrate Resistant Prostate Cancer The use of anti-androgens is standard treatment for prostate cancer patients in the management of PSA recurrence...Read More
Mark Pomerantz
Dr. Pomerantz earned a BS degree in American Studies from Yale University and an MD degree from Stanford University. He completed Medical Oncology Fellowship at the Dana-Farber Cancer Institute and...Read More